We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+0.58%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.66B
AUM Growth
-$16.4M
Cap. Flow
+$51.9M
Cap. Flow %
3.12%
Top 10 Hldgs %
60%
Holding
84
New
16
Increased
17
Reduced
16
Closed
20

Top Buys

Rank Stock Value
1
BOLT icon
Bolt Biotherapeutics
BOLT
+$89.6M
2
NXTC icon
NextCure
NXTC
+$32.2M
3
LLY icon
Eli Lilly
LLY
+$28.1M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$27.3M
5
ALGN icon
Align Technology
ALGN
+$25.2M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$89.4M
2
ABBV icon
AbbVie
ABBV
+$31.5M
3
AMGN icon
Amgen
AMGN
+$30M
4
UTHR icon
United Therapeutics
UTHR
+$22.2M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$14.4M

Sector Composition

Rank Sector Weight
1 Healthcare 93.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXEL icon
26
Exelixis
EXEL
$13.9B
$19M 1.14%
+839,181
New +$19M
PTGX icon
27
Protagonist Therapeutics
PTGX
$8.75B
$17M 1.02%
+654,900
New +$16.6M
OBSV
28
DELISTED
ObsEva SA Ordinary Shares
OBSV
$15.4M 0.93%
4,749,623
– –
QURE icon
29
uniQure
QURE
$2.68B
$14.4M 0.87%
+427,122
New +$15.3M
RGNX icon
30
Regenxbio
RGNX
$623M
$12.3M 0.74%
361,735
+90,621
+33% +$3.86M
HZNP
31
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$12.3M 0.74%
133,997
-79,393
-37% -$6.7M
VRTX icon
32
Vertex Pharmaceuticals
VRTX
$121B
$9.82M 0.59%
+45,700
New +$10M
DXCM icon
33
DexCom
DXCM
$27.6B
$9.7M 0.58%
+108,000
New +$10.1M
AMGN icon
34
Amgen
AMGN
$203B
$9.67M 0.58%
38,868
-125,795
-76% -$30M
AGEN
35
Agenus
AGEN
$249M
$9.46M 0.57%
+177,214
New +$12.8M
MIRM icon
36
Mirum Pharmaceuticals
MIRM
$6.89B
$9.44M 0.57%
476,401
+21,427
+5% +$410K
LONA
37
LeonaBio Inc
LONA
$69.4M
$9.37M 0.56%
50,917
– –
CCXI
38
DELISTED
ChemoCentryx, Inc.
CCXI
$9.22M 0.55%
179,999
+66,786
+59% +$4.02M
CYTK icon
39
Cytokinetics
CYTK
$11B
$9.06M 0.55%
389,720
-118,674
-23% -$2.53M
CCXI
40
PUT
DELISTED
ChemoCentryx, Inc.
CCXI
$7.69M 0.46%
+150,000
New +$9.02M
TCRR
41
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$7.43M 0.45%
336,682
+2,975
+0.9% +$81.1K
AMRN
42
Amarin Corp
AMRN
$284M
$7.27M 0.44%
58,529
– –
SNDX icon
43
Syndax Pharmaceuticals
SNDX
$1.84B
$6.68M 0.4%
298,644
-74,265
-20% -$1.68M
CHRS icon
44
Coherus Oncology
CHRS
$217M
$6.35M 0.38%
434,555
– –
ARNA
45
DELISTED
Arena Pharmaceuticals Inc
ARNA
$6.35M 0.38%
91,448
-29,925
-25% -$2.3M
MRNS
46
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$5.73M 0.34%
370,351
+96,324
+35% +$1.39M
JNCE
47
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$5.26M 0.32%
511,822
-413,458
-45% -$4.53M
PODD icon
48
Insulet
PODD
$11.3B
$4.57M 0.27%
+17,500
New +$4.69M
FATE icon
49
Fate Therapeutics
FATE
$281M
$4.52M 0.27%
54,795
+41,298
+306% +$3.96M
REPL icon
50
Replimune Group
REPL
$814M
$4.34M 0.26%
142,209
+122,209
+611% +$4.58M
1
2
3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q1 2021 Portfolio in Review

As of Q1 2021, Sofinnova Investments held 84 positions worth $1.66B, down 0.98% from $1.68B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Sofinnova Investments deployed $51.9M of net new capital in Q1 2021, opening 16 new positions and adding to 17 existing holdings. Its largest new stake was Bolt Biotherapeutics: 137,722 shares worth $90.6M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $89.4M trimmed.

  • Sofinnova Investments's largest Q1 2021 buy was Bolt Biotherapeutics: 137,722 shares worth $90.6M.
  • Sofinnova Investments added most to Eli Lilly in Q1 2021, an estimated $28.1M increase.
  • Sofinnova Investments's biggest Q1 2021 reduction was Ascendis Pharma A/S, cutting an estimated $89.4M.
  • Sofinnova Investments fully exited AbbVie in Q1 2021, selling an estimated $31.5M.
  • Sofinnova Investments's ten largest holdings make up 60% of its $1.66B portfolio in Q1 2021.
  • Sofinnova Investments opened 16 new positions and closed 20 in Q1 2021.
  • Sofinnova Investments's portfolio value fell 0.98% quarter-over-quarter to $1.66B.

Based on Sofinnova Investments's 13F filing for Q1 2021, filed 14 May 2021.